Thymalin

Grade C: Preliminary or limited human evidence

TL;DR: Thymalin is a calf-thymus polypeptide extract developed in the Soviet Union, with the first publications appearing around 1982 (PMID 7048731). Its human evidence base is large by volume but consists of uncontrolled and open-cohort studies, mostly in Russian-language literature; there is no independently confirmable randomized controlled trial. An open cohort reported lower respiratory-infection rates and reduced mortality in elderly participants (PMID 12577695), but because that work was not randomized or blinded, those figures are hypothesis-generating rather than established efficacy. PubMed-indexed work on human hematopoietic stem-cell differentiation (PMID 33237528) and on gene expression (PMID 37686182) is in vitro or in silico mechanistic research, not clinical evidence, and does not establish any COVID-19 benefit.

Key Takeaways

Grade C: Preliminary or limited human evidence
Not FDA approved: Not approved by the FDA for any indication. It is a complex biological thymus extract rather than a defined synthetic peptide.
Compounding: Not an FDA-approved drug. The compounding status of imported research peptides is unsettled and changing; confirm current legality with a licensed pharmacist or physician before any use.

Mechanism

A polypeptide complex extracted from calf thymus, proposed to support T-lymphocyte maturation as thymic function declines with age. The proposed immune-normalizing effect is based on in vitro and uncontrolled human observations, not controlled mechanistic studies.

Evidence

Thymalin is a calf-thymus polypeptide extract developed in the Soviet Union, with the first publications appearing around 1982 (PMID 7048731). Its human evidence base is large by volume but consists of uncontrolled and open-cohort studies, mostly in Russian-language literature; there is no independently confirmable randomized controlled trial. An open cohort reported lower respiratory-infection rates and reduced mortality in elderly participants (PMID 12577695), but because that work was not randomized or blinded, those figures are hypothesis-generating rather than established efficacy. PubMed-indexed work on human hematopoietic stem-cell differentiation (PMID 33237528) and on gene expression (PMID 37686182) is in vitro or in silico mechanistic research, not clinical evidence, and does not establish any COVID-19 benefit.

Safety and risks

No systematic safety data exist; the absence of reported signals reflects the uncontrolled nature of the studies rather than established tolerability. As a bovine thymus extract it is not chemically defined, which adds batch-to-batch variability, and theoretical concerns include allergic or hypersensitivity reactions and immune dysregulation. No safety data exist for use alongside immunosuppressants, cancer therapies, or autoimmune treatment.

Interactions

No controlled interaction data exist. Combining a thymic immunomodulator with immunosuppressive or other immunomodulatory therapy could produce unpredictable immune effects; people with autoimmune conditions or on biologics should not use it without specialist oversight.

Compounding legality

Not an FDA-approved drug. The compounding status of imported research peptides is unsettled and changing; confirm current legality with a licensed pharmacist or physician before any use.

Sources

Thymalin is Not FDA approved. PeptideGrids presents evidence and regulatory status for informational purposes only. We do not sell, supply, source, or help anyone obtain this compound, and we provide no dosing or administration guidance. This is not medical advice; consult a licensed clinician. Full disclaimer.

Last reviewed June 2, 2026 by PeptideGrids editorial team (independently audited).